May to June 2025

Reactogenicity, safety, and immunogenicity of Osivax’s NP-based OVX836 vaccine candidate co-administered with a licensed seasonal influenza vaccine in a Phase 2a trial NCT05284799, published in Groth 2025

Preclinical evaluation of intranasal delivery of a multi-subtype consensus NA-M2e VLP vaccine candidate, reported in Raha 2025

Development of recombinant H3 COBRA HA antigens using A(H3N2) HA sequences circulating from 2018-2022 to elicit broadly protective antibodies against A(H3N2) strains in animal models, reported in Allen 2025

Results of a Phase 3 trial NCT06097273 of Moderna’s mRNA-1083 combination COVID+influenza vaccine candidate, published in Rudman Spergel 2025

Preclinical evaluation of a centralized consensus NA immunogen delivered via an adenovirus vector, reported in Pekarek 2025

Results of a Phase 1/2 trial NCT05052697 of Pfizer’s next-generation quadrivalent mRNA vaccine candidate, qIRV, reported in Branche 2025

April to May 2025

EU-funded public-private partnership formed to develop Vivaldi's DeltaFLU vaccine candidate, announced in Cnossen 2025

US HHS funding announced to develop NIAID's BPL-1357, as noted in STAT and KFF Health News. Results of NIAID's BPL-1357 Phase 1 trial NCT05027932 posted on Clinicaltrials.gov

Analysis of broadly protective immune responses in newborn NHPs to NIAID’s HA-stem ferritin nanoparticle vaccine (H1ssF+AddaVax) in Crofts 2025

Results of Moderna's mRNA-1010 Phase 3 trials NCT05415462 and NCT05566639 published in Kandinov 2025

Analysis of B cell responses against broadly protective epitopes of the HA stalk domain following chimeric HA vaccination, published in Guthmiller 2025

New Phase 1 trial NCT06863142 of NIAID’s FluMos-v2 mosaic hexavalent nanoparticle vaccine with and without ALFQ adjuvant